Market Analysis

The Vaginal Speculum Market

The global market for vaginal specula was valued at over $3.58 billion in 2017, and is expected to grow at a rate of more than 1.55% over the seven year period from 2018-2025.

There are currently 9 major players in the vaginal speculum market with Welch Allyn, Teleflex, BD, and Integra Lifesciences accounting for about ¾ of the market. With over 60 million pap tests per year in the U.S., Feminora believes that our solution will disrupt the market and provide the best option for gynecological speculums because our product meets and solves most of the issues that others on the market are unable to.

Feminora's Market Strategy

Targets & Timeline

The OneSpec is a Class II medical device that requires FDA approval with a 510K application. Feminora aims to launch the product onto the market in 3 years post all validation testing and clinical trials.

We intend on focusing our efforts on initially marketing our OneSpec to clinics and private practices who are typically customers of the smaller brands that exist on the market. Because these practices are highly motivated to keep repeat customers, they are more likely to value the patient comfort out device provides. In comparison to large state-run hospitals that have many decision makers for purchasing decisions such as accountants, executives, and a staff of physicians, clinics and private practices are generally run by one physician, thus reducing the number of stakeholders we need to convince. We aim to market to at least 25% of these clinics within the first 2 years.